# Resource Summary Report

Generated by RRID on Aug 26, 2026

## pY109 (lenti-LbCpf1)

RRID:Addgene_84740
Type: Plasmid

### Proper Citation

RRID:Addgene_84740

### Plasmid Information

**URL:** http://www.addgene.org/84740

**Proper Citation:** RRID:Addgene_84740

**Insert Name:** huLbCpf1

**Organism:** Synthetic

**Bacterial Resistance:** Ampicillin

**Defining Citation:** PMID:27918548

**Vector Backbone Description:** Backbone Size:8069; Vector Backbone:pHKO_23; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

**Comments:** Contains a BsmBI cloning cassette for insertion of Cpf1 guides under U6 promoter control.

**Plasmid Name:** pY109 (lenti-LbCpf1)

**Record Creation Time:** 20220422T222546+0000

**Record Last Update:** 20260815T082118+0000

### Ratings and Alerts

No rating or validation information has been found for pY109 (lenti-LbCpf1).

No alerts have been found for pY109 (lenti-LbCpf1).

### Data and Source Information

**Source:** Addgene

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Fan M, et al. (2023) CRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 165, 115046.

Fan M, et al. (2022) A combinatorial CRISPR-Cas12a attack on HIV DNA. Molecular therapy. Methods & clinical development, 25, 43.

Gao Z, et al. (2020) Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA. Nucleic acids research, 48(10), 5527.

Breinig M, et al. (2019) Multiplexed orthogonal genome editing and transcriptional activation by Cas12a. Nature methods, 16(1), 51.

Gao Z, et al. (2019) A Single H1 Promoter Can Drive Both Guide RNA and Endonuclease Expression in the CRISPR-Cas9 System. Molecular therapy. Nucleic acids, 14, 32.

Chow RD, et al. (2018) Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion. Nature communications, 9(1), 1903.